Hierarchical beta zeolites with SiO2/Al2O3 molar ratios of 16 to 25 were obtained by alkaline treatment in NaOH solution. The effects of treatment temperature on crystallinity, textural properties and chemical composi...Hierarchical beta zeolites with SiO2/Al2O3 molar ratios of 16 to 25 were obtained by alkaline treatment in NaOH solution. The effects of treatment temperature on crystallinity, textural properties and chemical composites were studied by XRD, N2 sorption, FT-IR and XRF techniques. The desulfurization performance of parent and alkaline-treated beta zeolites was investigated by static absorption in four model fuels, containing four sulfur compounds of different molecular sizes like thiophene （TP）, 3-methylthiophene （3-MT）, benzothiophene （BT） and dibenzothiophene （DBT）, respectively. The crystallinity was observed to be successfully maintained when the treatment temperature was below 50 ℃. Mesoporosity of beta zeolite was evidently developed with alkaline treatment. The formation of mesopore remarkably improved the desulfurization performance for TP, 3-MT, BT and DBT, especially for DBT with larger molecular diameter. Though the addition of toluene in the model fuels resulted in a significant drop of the desulfurization performance of mesoporous beta zeolite, the introduction of cerium ions to some extent mitigated the effect of toluene, which means that both the adsorbent’s porous structure and the adsorption mode are responsible for the desulfurization performance. The adsorbent of cerium ion-exchanged mesoporous beta showed about 80% recovery of desulfurization after the first regeneration.展开更多
Sodium beta alumina（Na-β-alumina） films were synthesized by heat treatment of NaAl6O（9.5）and γ-NaA1O2 films at temperatures of 1 373-1 573 K.Single-phase γ-NaA1O2 and NaAl6O（9.5） films were prepared by laser ...Sodium beta alumina（Na-β-alumina） films were synthesized by heat treatment of NaAl6O（9.5）and γ-NaA1O2 films at temperatures of 1 373-1 573 K.Single-phase γ-NaA1O2 and NaAl6O（9.5） films were prepared by laser chemical vapor deposition at the deposition temperatures of 976 and 1 100 K,respectively.Subsequent heat treatment of the films resulted in the formation of Na-β-alumina with α-Al2O3 at temperatures above 1 373 K for NaAl6O（9.5） and 1 473 K for γ-NaA1O2.On heat treatment at temperatures of 1 473-1 573 K,the faceted morphology with terraces of the as-deposited（110）-oriented γ-NaAlO2 films transformed to a porous morphology with platelet grains comprising Na-β-alumina and α-Al2O3.On heat treatment at temperatures of1 373-1 473 K,the pyramidal,faceted grains of as-deposited NaAl6O（9.5） films transformed to planer,shapeanisotropic morphology in the film of mixed Na-β-alumina and α-Al2O3.A dense morphology was observed in both the as-deposited and heat-treated NaAl6O（9.5） films.展开更多
The stability of beta zeollie in acid solution and the effect of acid treatment on the polymorphs in beta zeolite were studied. This zeolite is easily dealuminated by HCI treatment but its framework highly resistent t...The stability of beta zeollie in acid solution and the effect of acid treatment on the polymorphs in beta zeolite were studied. This zeolite is easily dealuminated by HCI treatment but its framework highly resistent to acidity.In β zeolite, polymorph A is less stable than polymorph B.The chirality of β zeolite can be modified by the method of acid treatment.展开更多
通过水热处理、柠檬酸处理及其复合处理对Beta分子筛进行后改性,并以改性后的载体制得铂/Beta催化剂。采用X射线衍射(XRD)、X射线荧光光谱仪(XRF)、程序升温脱附(NH3-TPD)、红外吡啶吸附(Py-IR)、骨架铝核磁共振技术(~(27)Al MAS NMR)...通过水热处理、柠檬酸处理及其复合处理对Beta分子筛进行后改性,并以改性后的载体制得铂/Beta催化剂。采用X射线衍射(XRD)、X射线荧光光谱仪(XRF)、程序升温脱附(NH3-TPD)、红外吡啶吸附(Py-IR)、骨架铝核磁共振技术(~(27)Al MAS NMR)及骨架硅核磁共振技术(~(29)Si MAS NMR)等表征了改性前后Beta分子筛的物化性质,并考察了改性前后铂/Beta的多环芳烃选择性开环性能。结果表明,Beta分子筛在柠檬酸处理过程中可同时发生络合脱铝与骨架补铝,实现骨架铝的再分布;Beta分子筛在水热处理过程中优先脱除稳定性相对较低的Si(2 Al)处骨架铝,产生骨架缺陷的同时生成一定比例的二次介孔结构;水热-柠檬酸复合处理影响Beta分子筛骨架补铝及骨架铝再分布的效果,水热处理后Beta分子筛中存在更多的骨架缺陷,促进活性Al(OH)_(2)^(+)物种的骨架补铝作用。当Beta分子筛采用水热-柠檬酸复合处理顺序时,骨架补铝及骨架铝再分布效果显著,样品以中强酸为主,且具有较高的B酸量与L酸量的比值,所制备催化剂的多环芳烃选择性开环活性及稳定性最优。展开更多
Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acut...Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.展开更多
基金supported by the Fundamental Research Funds for the Central Universities(No.DUT10LK25)the Natural Science Foundation of China(No.21106014)
文摘Hierarchical beta zeolites with SiO2/Al2O3 molar ratios of 16 to 25 were obtained by alkaline treatment in NaOH solution. The effects of treatment temperature on crystallinity, textural properties and chemical composites were studied by XRD, N2 sorption, FT-IR and XRF techniques. The desulfurization performance of parent and alkaline-treated beta zeolites was investigated by static absorption in four model fuels, containing four sulfur compounds of different molecular sizes like thiophene （TP）, 3-methylthiophene （3-MT）, benzothiophene （BT） and dibenzothiophene （DBT）, respectively. The crystallinity was observed to be successfully maintained when the treatment temperature was below 50 ℃. Mesoporosity of beta zeolite was evidently developed with alkaline treatment. The formation of mesopore remarkably improved the desulfurization performance for TP, 3-MT, BT and DBT, especially for DBT with larger molecular diameter. Though the addition of toluene in the model fuels resulted in a significant drop of the desulfurization performance of mesoporous beta zeolite, the introduction of cerium ions to some extent mitigated the effect of toluene, which means that both the adsorbent’s porous structure and the adsorption mode are responsible for the desulfurization performance. The adsorbent of cerium ion-exchanged mesoporous beta showed about 80% recovery of desulfurization after the first regeneration.
基金Funded by the Ministry of Education,Culture,Sports,Science and Technology,a Grant-in-Aid for Challenging Exploratory Research(No.26560235)the ARCMG–IMR Cooperative Program(No.14G0402)of Tohoku Universitythe China Scholarship Council and the 111 Project(No.B13035)of China
文摘Sodium beta alumina（Na-β-alumina） films were synthesized by heat treatment of NaAl6O（9.5）and γ-NaA1O2 films at temperatures of 1 373-1 573 K.Single-phase γ-NaA1O2 and NaAl6O（9.5） films were prepared by laser chemical vapor deposition at the deposition temperatures of 976 and 1 100 K,respectively.Subsequent heat treatment of the films resulted in the formation of Na-β-alumina with α-Al2O3 at temperatures above 1 373 K for NaAl6O（9.5） and 1 473 K for γ-NaA1O2.On heat treatment at temperatures of 1 473-1 573 K,the faceted morphology with terraces of the as-deposited（110）-oriented γ-NaAlO2 films transformed to a porous morphology with platelet grains comprising Na-β-alumina and α-Al2O3.On heat treatment at temperatures of1 373-1 473 K,the pyramidal,faceted grains of as-deposited NaAl6O（9.5） films transformed to planer,shapeanisotropic morphology in the film of mixed Na-β-alumina and α-Al2O3.A dense morphology was observed in both the as-deposited and heat-treated NaAl6O（9.5） films.
文摘The stability of beta zeollie in acid solution and the effect of acid treatment on the polymorphs in beta zeolite were studied. This zeolite is easily dealuminated by HCI treatment but its framework highly resistent to acidity.In β zeolite, polymorph A is less stable than polymorph B.The chirality of β zeolite can be modified by the method of acid treatment.
文摘通过水热处理、柠檬酸处理及其复合处理对Beta分子筛进行后改性,并以改性后的载体制得铂/Beta催化剂。采用X射线衍射(XRD)、X射线荧光光谱仪(XRF)、程序升温脱附(NH3-TPD)、红外吡啶吸附(Py-IR)、骨架铝核磁共振技术(~(27)Al MAS NMR)及骨架硅核磁共振技术(~(29)Si MAS NMR)等表征了改性前后Beta分子筛的物化性质,并考察了改性前后铂/Beta的多环芳烃选择性开环性能。结果表明,Beta分子筛在柠檬酸处理过程中可同时发生络合脱铝与骨架补铝,实现骨架铝的再分布;Beta分子筛在水热处理过程中优先脱除稳定性相对较低的Si(2 Al)处骨架铝,产生骨架缺陷的同时生成一定比例的二次介孔结构;水热-柠檬酸复合处理影响Beta分子筛骨架补铝及骨架铝再分布的效果,水热处理后Beta分子筛中存在更多的骨架缺陷,促进活性Al(OH)_(2)^(+)物种的骨架补铝作用。当Beta分子筛采用水热-柠檬酸复合处理顺序时,骨架补铝及骨架铝再分布效果显著,样品以中强酸为主,且具有较高的B酸量与L酸量的比值,所制备催化剂的多环芳烃选择性开环活性及稳定性最优。
文摘Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.
